What is the Role for TKIs in RCC? Highlights from the 18th Annual Meeting of the SUO


Manage episode 221246482 series 1452688
By Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio streamed directly from their servers.
Host: Barnett Mennen, MD
Guest: Vitaly Margulis, MD
Jointly provided by and

Although renal cell carcinoma (RCC) accounts for only 2% to 3% of all adult cancers, for those who present with or progress to advanced RCC, the 5-year survival rate has never been above 10%. Several tyrosine-kinase inhibitors (TKIs), along with many other therapies, now occupy a preferred role in treatment of patients with advanced RCC, but this is a rapidly changing field. The emergence of immunotherapy for patients with RCC is reshaping the landscape of treatment options for both patients with relapse/stage IV surgically unresectable RCC and neoadjuvant therapy. Moreover, advances in the understanding of RCC biomarkers may help to identify which patients may benefit from certain therapies allowing for the possibility of more individualized treatment plans. This interactive activity features an interview with a leading expert in RCC as he discusses the current trends in clinical research in RCC treatment and how these findings are expected to impact not only guideline development but also more individualized patient care. This expert interview was recorded at and discusses some of the latest data featured at the 18th Annual Meeting of ...

135 episodes available. A new episode about every 33 days averaging 0 mins duration .